

A Note from Brookline Capital Markets

Recognizing the Robust Performance of the Genelux Corporation Initial Public Offering

About the Offering

On January 25, 2023, Genelux Corporation (“Genelux”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, priced its initial public offering of 2,500,000 shares at a price to the public of \$6.00 per share, for total gross proceeds of \$15,000,000, or \$15,918,000 after the underwriters exercised an additional overallotment of 153,000 shares.

Brookline Capital Markets, a division of Arcadia Securities, LLC, served as joint-bookrunning manager.

This offering represents one of only three Life Sciences, Med. Tech, and Diagnostics IPOs in 2023, and marked the first IPO since November of 2022.

Post-Pricing Performance

The stock closed at \$24.15 on March 16th, 2023, representing a return of **302%** over the IPO price of \$6.00.

This remarkable debut is a testament to the tremendous potential of Genelux’s innovative approach to developing cancer treatments. The company’s proprietary platform, which leverages oncolytic viruses to selectively target and destroy cancer cells, represents a promising new frontier in cancer therapy.

Genelux’s IPO also highlights the ongoing investor interest in the biotechnology sector, which has been fueled by recent breakthroughs in gene editing, cell therapy, and immunotherapy. As more and more companies like Genelux are able to develop and commercialize novel treatments, we believe that the biotech industry will continue to be a significant driver of innovation and growth.

At this time, we would like to congratulate Genelux on its successful IPO and wish the company all the best as it continues to advance its groundbreaking research. We would also like to thank our investors for their support and confidence in us as we continue to identify and support companies that have the potential to change the world.

Brookline Capital Markets’ Suite of Finance Solutions

At Brookline, we pride ourselves on our ability to partner with private corporate clients from inception to IPO. We have established a market-leading platform in the pre-IPO healthcare investment banking arena. Our premier public capital markets franchise dedicates itself to raising capital in the IPO, follow-on, PIPE and convertible markets, as well as to providing capital markets advisory services to its roster of clients.

We stand ready to provide value-added investment banking advice, analysis, and execution for our healthcare corporate clients at any point of clinical development or financial maturity.

Brookline’s public capital markets services include:

- **Equity Underwriting:** Initial Public Offerings, Follow-On Offerings, Confidentially Marketed Public Offerings (“CMPOs”), and Registered Direct Offerings (“RDs”)
- **Private Placements:** Private Investment in Public Equity Financings (“PIPEs”)
- **Advisory:** IPO Advisory, Capital Markets Advisory, and Strategic Advisory

** Obtained from sources believed to be reliable including: FactSet, SEC filings and the Company website*

Legal Disclaimer

This publication is prepared by the Equities Department of Brookline Capital Markets, a division of Arcadia Securities, LLC ("Brookline") and is not the product of Brookline's Equity Research Department. This publication is provided for informational purposes only, and it is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This publication contains market prices, statistical data and other information (collectively, "Information") from third-party sources believed by Brookline to be reliable. Such Information, however, is neither all-inclusive nor guaranteed or warranted by Brookline to be accurate or complete, and it should not be relied upon as such. Such Information is also subject to change, without notice, and Brookline does not undertake to advise recipients of this publication of changes, if any. Past performance is not a guarantee of future results, and Brookline makes no representation or warranty, express or implied, in respect of future performance of any security (or any grouping of securities) mentioned in this publication. The price of the securities mentioned in this publication and the income they produce may fluctuate and/or be adversely affected by, among other things, exchange rates and/or market conditions, and investors may realize losses on investments in such securities, including the loss of investment principal. Brookline accepts no liability for any loss arising from the use of information contained in this publication, except to the extent that liability may arise under specific statutes or regulations applicable to Brookline.

In the course of its regular business, Brookline may be long or short in the securities mentioned in this publication and may make purchases and/or sales of them or options to purchase or sell them from time to time in the open market, as a market maker or otherwise, including purchases from or sales to customers on a principal basis. In addition, Brookline may perform or seek to perform investment banking services for the issuers of the securities mentioned in this publication in the next three months and may have received compensation for such services within the last 12 months.

Member FINRA and SIPC

© 2023 Brookline Capital Markets. All rights reserved. Unauthorized use, distribution, duplication or disclosure without the prior written permission of Brookline in each instance is prohibited.